ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours

BACKGROUND: There is a considerable body of pre-clinical, epidemiological and randomised data to support the hypothesis that aspirin has the potential to be an effective adjuvant cancer therapy. METHODS: Add-Aspirin is a phase III, multi-centre, double-blind, placebo-controlled randomised trial with...

Descripción completa

Detalles Bibliográficos
Autores principales: Coyle, Christopher, Cafferty, Fay H., Rowley, Samuel, MacKenzie, Mairead, Berkman, Lindy, Gupta, Sudeep, Pramesh, C S, Gilbert, Duncan, Kynaston, Howard, Cameron, David, Wilson, Richard H., Ring, Alistair, Langley, Ruth E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5127874/
https://www.ncbi.nlm.nih.gov/pubmed/27777129
http://dx.doi.org/10.1016/j.cct.2016.10.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5127874/
https://www.ncbi.nlm.nih.gov/pubmed/27777129
http://dx.doi.org/10.1016/j.cct.2016.10.004

Ejemplares similares